Embark on our journey in personalised medicines

To bring CAR T therapies closer to patients in Europe, we are building our first European CAR T cell therapy production centre in Leiden, the Netherlands.
,
EA4C17

Follow the latest news

group photo
group photo

May 2022

13 new colleagues joined!

We had the pleasure to welcome more new colleagues in Leiden, where we are building our first European Cell therapy production site.

If you are keen to join our team in Leiden to bring CAR T cell therapy closer to cancer patients in Europe, click here to view a list of our current open roles: career page.

13 May 2022

Progress with the steelwork

Excellent progress has been made with the steelwork. The building is shaping up nicely and all construction works are progressing according to plan. Stay tuned!

Leiden metal framework

13 May 2022

Progress with the steelwork

Excellent progress has been made with the steelwork. The building is shaping up nicely and all construction works are progressing according to plan. Stay tuned!

li post innovationquarter
li post innovationquarter

2 May 2022

Interview with Arjen Schippers and InnovationQuarter

Read the interview with Arjen Schippers, Senior Director and Program Head of Europe Cell Therapy Facility at Bristol Myers Squibb about what he has worked on over the last year with support from InnovationQuarter and what can be expected in the coming months.

Read the full article by clicking on this link.

March 2022

9 more colleagues joined us at Leiden

An extra 9 colleagues have chosen a career where their work will change the lives of patients. We are still looking for many profiles, if ground-breaking work drives you, join us in helping to bring cancer-fighting CAR T Cell Therapies to patients across Europe.

Construction site with machine

March 2022

9 more colleagues joined us at Leiden

An extra 9 colleagues have chosen a career where their work will change the lives of patients. We are still looking for many profiles, if ground-breaking work drives you, join us in helping to bring cancer-fighting CAR T Cell Therapies to patients across Europe.

logo bcf
logo bcf

15 February 2022

Virtual Career Event BCF Career

Arjan Schippers welcomed many interested potential co-workers for the new CAR T Cell Therapy facility in Leiden. He talked about how you can create a meaningful career and bring new hope to cancer patients.

Join BMS in Leiden, and you'll work alongside the best and the brightest of the healthcare industry to try new things, solve the toughest challenges and create miracles. See our spotlight vacancies

February 2022

First steel is going up

It's full steam ahead on our Leiden construction site. The first steel nearly arrived, and is up already. So far, the construction of our very first European cell therapy facility in Leiden is progressing as planned. Stay tuned!

Three workers in helmets standing in front of building site

February 2022

First steel is going up

It's full steam ahead on our Leiden construction site. The first steel nearly arrived, and is up already. So far, the construction of our very first European cell therapy facility in Leiden is progressing as planned. Stay tuned!

Three workers in helmets standing in front of building site
Three workers in helmets standing in front of building site

January 2022

Foundation works completed

In January, we lay the foundation of the building. It will essentially be standing on 591 piles driven to a depth of 30 meters through soil, then sea water to reach deep compacted sand. We have successfully installed almost all 591 piles and completed on track this month. 

October 2021

BCF Career Event in Utrecht 

We are present at the BCF Career Event in Utrecht, the largest science job fair.  What an energy we felt to meet again in-person and to tell how we transform the lives of millions of people through innovation and science. 

We are hiring for our first cell therapy facility in Leiden, and we have some great opportunities. Check the spotlight vacancies here.

Three workers in helmets standing in front of building site

October 2021

BCF Career Event in Utrecht 

We are present at the BCF Career Event in Utrecht, the largest science job fair.  What an energy we felt to meet again in-person and to tell how we transform the lives of millions of people through innovation and science. 

We are hiring for our first cell therapy facility in Leiden, and we have some great opportunities. Check the spotlight vacancies here.

Three workers in helmets standing in front of building site
Three workers in helmets standing in front of building site

28 October 2021

Bristol Myers Squibb starts construction of its European therapy facility and marks it with a Celebration Event

Bristol Myers Squibb celebrated the start of the construction of its first European cell therapy facility at the Leiden Bio Science Park in the Netherlands.

The celebration event was concluded with Arjen Schippers, Program Head of Europe Cell Therapy Facility, raising the flag on the new site: “Like the first man on the moon, I am really honoured to plant the BMS flag in Europe. Let this be the symbol of our commitment to discover, develop and deliver innovative medicines to help patients prevail over serious diseases.”

22 April 2021

Bristol Myers Squibb chooses Leiden Bio Science Park as the European site for a new CAR T cell therapy facility

By building this production facility, BMS is investing in the expansion of its global network to bring cell therapy closer to the European patient. In doing so, the organisation is expanding its capacity to treat patients.

Three workers in helmets standing in front of building site

22 April 2021

Bristol Myers Squibb chooses Leiden Bio Science Park as the European site for a new CAR T cell therapy facility

By building this production facility, BMS is investing in the expansion of its global network to bring cell therapy closer to the European patient. In doing so, the organisation is expanding its capacity to treat patients.

Three workers in helmets standing in front of building site
Three workers in helmets standing in front of building site

2019

Bristol Myers Squibb acquires Celgene 

Bristol Myers Squibb and Celgene come together to create a leading biopharma company positioned to address the needs of patients with serious diseases.

2017

FDA approves First CAR T therapy 

The first CAR T therapy is approved in 2017 for the treatment of young adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia. 

CAR T Therapy

2017

FDA approves First CAR T therapy 

The first CAR T therapy is approved in 2017 for the treatment of young adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia. 

CAR T cells and blood cancer
CAR T cells and blood cancer

2016

CAR T Cells Show Promise in Blood Cancers

Multiple clinical trials show CAR T cell therapy has promising results in treating patients with relapsed or refractory B- cell malignancies, including acute and chronic lymphocytic leukemia, which typically all have a poor prognosis despite the use of aggressive therapies.

2015

First Approved PD-1 Inhibitors

Following the approval of the first anti-CTLA-4 therapy three years earlier, nivolumab, one the first anti-PD-1 therapies, is approved by the FDA. This anti-PD1 antibody drug targets the PD-1 receptor in the patient’s body, which is the protein on the surface of cells that has a role in regulating the immune system’s response.

T cell and tumor cell

2015

First Approved PD-1 Inhibitors

Following the approval of the first anti-CTLA-4 therapy three years earlier, nivolumab, one the first anti-PD-1 therapies, is approved by the FDA. This anti-PD1 antibody drug targets the PD-1 receptor in the patient’s body, which is the protein on the surface of cells that has a role in regulating the immune system’s response.

IO/IO clinical trials
IO/IO clinical trials

2013

Initiation of I-O/I-O Combination Clinical Trials

Initiation of the first late-stage I-O/I-O combination clinical trials combining a CTLA-4 inhibitor with a PD-1 inhibitor. This trial contributes to the approval of the first I-O/I-O combination treatment in 2015.

Cancer Immunotherapy Named “Breakthrough of the Year”

Science Magazine names cancer immunotherapy as the “Breakthrough of the Year” following a period of significant advancement in I-O research.

2012

CAR T Therapy Shows Promise in Cancer Treatment

Emma Whitehead, a six-year-old with acute lymphoblastic leukemia, receives an experimental treatment that used a disabled form of the HIV virus to reset the immune system to kill cancer cells genetically. The successful treatment helped to launch the explosion of CAR T development. 

CAR T Therapy for cancer treatment

2012

CAR T Therapy Shows Promise in Cancer Treatment

Emma Whitehead, a six-year-old with acute lymphoblastic leukemia, receives an experimental treatment that used a disabled form of the HIV virus to reset the immune system to kill cancer cells genetically. The successful treatment helped to launch the explosion of CAR T development. 

I-O therapy
I-O therapy

2011

The first modern I-O therapy

In 2011, Bristol Myers Squibb brought the first modern cancer I-O therapy to patients by launching ipilimumab, the first anti-CTLA 4 therapy, in 2011 to treat metastatic melanoma. The approval encourages further study of I-O treatments and drives more than one thousand clinical trials in the years that follow. 

2010

D-L1 Identified as a Biomarker of Response to Anti-PD-1 Therapy

An early clinical study evaluating PD-1 inhibition provides the first piece of evidence that expression of PD-L1 (a cell surface protein involved in immune response) may be a predictive biomarker of response to I-O therapy.

Scientist hands

2010

D-L1 Identified as a Biomarker of Response to Anti-PD-1 Therapy

An early clinical study evaluating PD-1 inhibition provides the first piece of evidence that expression of PD-L1 (a cell surface protein involved in immune response) may be a predictive biomarker of response to I-O therapy.

Genome
Genome

2003

The Human Genome Project Concludes

The Human Genome Project, the world’s largest collaborative biological project, concludes its 13-year program determining the sequence of chemical base pairs that make up human DNA and mapping the human genome. This research continues to help scientists identify genetic changes and malfunctions that contribute to cancer.

1993

CAR T is born

The first CAR T cells are made by Israeli immunologist Zelig Eshhar. Eshhar and his colleagues demonstrate that CAR T cell therapy could redirect T cell killing to foreign proteins.

CAR T Cells treatment for cancer

1993

CAR T is born

The first CAR T cells are made by Israeli immunologist Zelig Eshhar. Eshhar and his colleagues demonstrate that CAR T cell therapy could redirect T cell killing to foreign proteins.

Taxane-Based Chemotherapy
Taxane-Based Chemotherapy

1991

Taxane-Based Chemotherapy

The National Cancer Institute signs a Cooperative Research and Development Agreement (CRADA) with Bristol Myers Squibb to help develop a taxane-based chemotherapy originally derived from the bark of the Pacific yew tree. The medicine is eventually approved for multiple indications, including breast, ovarian and lung cancer. Over time, taxane-based chemotherapy has become a mainstay in cancer treatment due to its unique mechanism of action.

1952 - 1980

Major Advances in New Cancer Treatments Approved by the FDA

As of 1952, advances in cancer research drive a wave of new cancer drug approvals, with more than 20 new therapies launched over the next three decades, such as  HYDREA® (hydroxyurea), Squibb’s first anti-cancer treatment in 1967 or the introduction by Bristol Laboratories of MUTAMYCIN® (mytomycin) for the treatment of bone cancer and stomach and pancreatic tumors, cancer chemotherapy agent Blenoxane® (bleomycin sulfate) for the treatment of squamous cell cancers, head and neck cancers and Hodgkin’s and non-Hodgkin’s lymphomas, and many more.

Cancer cells

1952 - 1980

Major Advances in New Cancer Treatments Approved by the FDA

As of 1952, advances in cancer research drive a wave of new cancer drug approvals, with more than 20 new therapies launched over the next three decades, such as  HYDREA® (hydroxyurea), Squibb’s first anti-cancer treatment in 1967 or the introduction by Bristol Laboratories of MUTAMYCIN® (mytomycin) for the treatment of bone cancer and stomach and pancreatic tumors, cancer chemotherapy agent Blenoxane® (bleomycin sulfate) for the treatment of squamous cell cancers, head and neck cancers and Hodgkin’s and non-Hodgkin’s lymphomas, and many more.